Appian Announces New Integration with Google Cloud Contact

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2018
169
Appian Announces New Integration with Google Cloud Contact Center AI

RESTON, Va., July 24, 2018 (GLOBE NEWSWIRE) -- Appian (NASDAQ: APPN ) today announced integration with Google Cloud’s new Contact Center AI, a solution that combines multiple AI products to improve customer service experience and the productivity of contact centers.This further demonstrates Appian’s commitment to delivering an integrated customer experience across channels and customer touchpoints with Appian’s Intelligent Contact Center™ (ICC) Platform .

The Appian ICC platform provides native and integrated artificial intelligence (AI) capabilities, based on a low-code platform, for building omni-channel customer engagement, case management, and intelligent automation solutions. Through this partnership, Appian ICC customers will be able to integrate into the three main products of Google’s Cloud Contact Center AI; Virtual Agent, Agent Assist and Analytics. These tools leverage AI bots to interact with customers, manage the bots to ensure proper function and analyze all activity to maximize the customer experience, while ICC uses Appian Records to give these bots a complete view of the customer in every interaction.

Key features of Appian’s integration with Contact Center AI include:

  • Unified Agent Experience with Omni-Channel Integrations – It is now possible to integrate with Google Cloud for telephony, chat, text message and social media with Appian’s dynamic case management and intelligent automation capabilities to streamline the customer experience and speed up case resolution.
  • Robust Intelligent Automation: Automating tasks increases the productivity and effectiveness of agents. When leveraging Appian’s Business Process Management (BPM), Robotic Process Automation (RPA), and AI to orchestrate processes, integrate systems, and apply business rules contact centers are able to intelligently automate any agent and customer interaction.
  • Dynamic Case Management – Customers can achieve a single view of the customer and support high-end problem solving for complex interactions. Appian unifies the interactions between people, process, data, and content to create powerful interface that arms agents with provide accurate information and reach resolution faster.
  • Low-Code Cloud Platform - Appian customers can adopt a cloud strategy with a low-code application development platform allowing for rapid delivery and adaptive change on enterprise  applications that meet security, confidentiality and compliance controls.

“Appian provides customers a powerful, low-code platform to help them improve their customers' satisfaction, and increase their operational and agent efficiencies in the contact center,” said Medhat Galal, VP of Product Solutions. “By integrating with Google Cloud Contact Center AI, we bring strong AI-Powered applications to the contact center market that can be leveraged for a powerful customer experience.”

The results customers have garnered using Appian’s platform showcase the tremendous value and impact intelligent automation can have on an organization. A well-known global financial services company reported an increase of 64% in customer satisfaction scores within just one month by prioritizing omni-channel customer engagement. They integrated systems and channels into one cohesive interface. In addition, one of the largest insurers in the UK leveraged Appian’s intelligent automation to reinvent their contact center operations and improve customer satisfaction. The impact has been a nine times acceleration in customer service response time and 40% operational cost savings.

“Contact Center AI empowers enterprises to use AI to complement and enhance their contact centers,” said Rajen Sheth, Director of Product Management. “Google Cloud’s goal is to make it as easy as possible for our customers to use AI for contact centers through our relationships with key partners like Appian.”

For more information, visit Appian’s website .

Forward-Looking Statements

This press release includes forward-looking statements. All statements contained in this press release other than statements of historical facts, including, without limitation, statements regarding Appian’s integration with Google Cloud’s new Contact Center AI and the results to be obtained by Appian ICC customers through such integration are forward-looking statements. The words “anticipate,” believe,” “continue,” “estimate,” “expect,” “intend,” “may,” “will” and similar expressions are intended to identify forward-looking statements. Appian has based these forward-looking statements largely on its current expectations and projections about future events and financial trends that Appian believes may affect its financial condition, results of operations, business strategy, short-term and long-term business operations and objectives and financial needs. Those forward-looking statements are subject to a number of risks and uncertainties, including, without limitation, risks related to Appian’s ability to provide a platform that is useful to its customers, including through offering new or enhanced solutions, risks related to the success of Appian’s strategic relationships with third parties, risks related to Appian’s ability to integrate the Appian platform with third-party applications and platforms and the risks and uncertainties set forth in the “Risk Factors” section of Appian’s Annual Report on Form 10-K for the year ended December 31, 2017 filed with the Securities and Exchange Commission, and subsequent reports that Appian has filed with the Securities and Exchange Commission. Moreover, Appian operates in a very competitive and rapidly changing environment. New risks emerge from time to time. It is not possible for Appian’s management to predict all risks, nor can Appian assess the impact of all factors on its business or the extent to which any factor, or combination of factors, may cause actual results to differ materially from those contained in any forward-looking statements Appian may make. In light of these risks, uncertainties and assumptions, Appian cannot guarantee future results, levels of activity, performance, achievements or events and circumstances reflected in the forward-looking statements will occur. Appian is under no duty to update any of these forward-looking statements after the date of this press release to conform these statements to actual results or revised expectations, except as required by law.

For Information Contact: Nicole Greggs Director of Media Relations +1 703-260-7868 nicole.greggs@appian.com

 

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Innovent's SINTBILO® Hits Primary Endpoint in Study

Updated Category News Views 78

Innovent's Latest Breakthrough with SINTBILO® One moment you're sipping coffee, the next you're staring at a clinical milestone. Innovent Biologics has shouted from the rooftops that their drug, SINTBILO® (tafolecimab injection), has wrapped up its Phase 3 CREDIT-5 study, snagging the primary endpoint with both hands. This isn't just any drug; it's marked as the first...

Continue Reading
Webull Faces Class Action Suit: Key Deadlines Loom

Updated Category News Views 236

The Clock is Ticking for Webull Investors If anyone's got a Webull stake, listen up! You’ve got a deadline that's staring you in the face: December 7, 2026. This is when you need to throw your hat in the ring to be a lead plaintiff in the Webull Corporation class action. We're talking securities fraud, folks, with allegations flying that would make your head spin....

Continue Reading
JNJ's Dual-Antigen Therapy Shows Promise in Prostate Cancer

Updated Category News Views 273

Exploring a New Front in Cancer Treatment Johnson & Johnson (NYSE: JNJ) just dropped a bombshell at the Society for Immunotherapy of Cancer (SITC) 2026 Annual Meeting, unveiling data that could reshape prostate cancer care. Their pioneering combo of pasritamig and JNJ-9401, a dual-antigen-targeted therapy, has the scientific community buzzing. Yeah, it's just Phase 1 baby...

Continue Reading
Novo's Semaglutide Shows Promise in MASH Study

Updated Category News Views 337

Semaglutide, a name on the lips of many investors looking for breakthroughs, is making waves again. This time, the stir comes from recent findings in the MASH field, and it's got folks in white coats quite excited. Revolutionary Results from Novo Novo Nordisk has announced promising results from their phase 3 ESSENCE trial that looks into semaglutide's effects on a...

Continue Reading
MWC26 Doha: Bridging Standards for MENA's Future

Updated Category News Views 501

MWC26 Doha Launches with a Connectivity Mission Forget corporate boardrooms; the real action this week is unfolding in Doha's bustling exhibition halls. Kicked off with the fanfare you'd expect from such a key event, MWC26 Doha has drawn a crowd that's got both tech geeks and policy wonks nodding with interest. This ain’t your average trade show: it’s the melting pot...

Continue Reading
LG's ASIL D Certification: A Game Changer in Autos

Updated Category News Views 15

Why LG's ASIL D Certification Matters There ain't much in the tangled mess of automotive innovations these days that'll make a seasoned investor raise an eyebrow, but here comes LG Electronics grabbing the ASIL D certification like it's a badge of market honor. The ISO 26262 ASIL D is no walk in the park, folks—it's the top rung on the safety ladder, something that's...

Continue Reading
GlycoNex Eyes Japanese Market with Denosumab Biosimilar

Updated Category News Views 45

A Strategic Step into the Japanese Market Alright folks, there's a new kid aiming to shake things up in the biotech neighborhood, and it's GlycoNex with its denosumab biosimilar, SPD8. These guys just tossed their hat in the ring with a regulatory submission to Japan's Pharmaceuticals and Medical Devices Agency (PMDA). If the cosmic forces align, they might snag an...

Continue Reading
Antengene’s AnTenGager-D2 Advances in Cancer Treatment

Updated Category News Views 31

Antengene's AnTenGager-D2 Offers Fresh Hope Alright, let's dig into the latest buzz from the 2026 Society for Immunotherapy of Cancer conference about Antengene's AnTenGager-D2 platform. If you're not into biotech lingo, buckle up, because this is a ride into the future of cancer treatments—where science fiction might soon become science fact. A Novel Approach to Tumor...

Continue Reading
FFR's OmniMind Takes Top Spot In RoboColiseum Rankings

Updated Category News Views 55

The AI Race Heats Up with FFR's Big Win Stop the presses—FFR's OmniMind AI just snagged the top spot on RoboColiseum's global rankings. Yeah, you heard right, this ain't just some run-of-the-mill news. As of November 6, they've parked themselves in pole position, beating out heavyweights like NVIDIA's GR00T N1.7 and GPT-6 Astra. That's like hitting a grand slam right...

Continue Reading
CureGene's Evategrel Aims for Breakthrough in Stroke Care

Updated Category News Views 69

Revolutionizing Stroke Care: Enter Evategrel When it comes to strokes, time is money—and I'm telling you, this ain't an area where you can afford to twiddle your thumbs. The faster you can get that blood flowing again, the better the chance you've got of walking away with less damage. That's where CureGene's new investigational drug, Evategrel, comes in. Why Evategrel...

Continue Reading

Top 5 Most Recently Viewed Articles

Eco Wave Power Expands Wave Energy Project in Europe

Updated Category News Views 229

Eco Wave Power Initiates Key Infrastructure Enhancements Eco Wave Power Global AB (publ) (NASDAQ: WAVE) is excited to unveil plans for crucial upgrades at its groundbreaking wave energy project. This groundbreaking initiative is set to harness ocean wave energy to produce clean electricity efficiently. Eco Wave Power, recognized as a leading company in onshore wave energy...

Continue Reading
Key Managerial Transactions Reported by Danske Bank A/S

Updated Category News Views 162

Recent Mandatory Transaction Notifications by Danske Bank A/S Danske Bank A/S is committed to transparency in financial transactions involving its managerial personnel. This communication signifies the bank's adherence to the EU Market Abuse Regulation and the requirements set by the Danish Financial Supervisory Authority (FSA) and Nasdaq Copenhagen. Understanding...

Continue Reading
Strategic Insights into Symbotic's Options Market Activity

Updated Category News Views 187

Overview of Options Activity for Symbotic Recently, significant investors have demonstrated a notably bearish outlook on Symbotic. This trend has been evidenced by the options activity surrounding the company's stock, symbolized by SYM. The strong presence of whales entering the market indicates a shift in investor sentiment, with nuances that are crucial for...

Continue Reading
South Coast AQMD Takes Action on Oil Facilities During Violations

Updated Category News Views 267

South Coast AQMD Addresses Oil Site Violations In a determined effort to safeguard public health and air quality, the South Coast Air Quality Management District (South Coast AQMD) has recently taken enforcement action against three oil and gas facilities in Los Angeles. These actions were prompted by public complaints and confirmed violations of air quality regulations,...

Continue Reading
BAM UK & Ireland and LoadSpring Solutions Innovate Project Management

Updated Category News Views 199

BAM UK & Ireland and LoadSpring Solutions Innovate Project Management BAM UK & Ireland, a prominent name in the construction and engineering sector, has taken a bold step forward by partnering with LoadSpring Solutions. This collaboration aims to revolutionize project management through an innovative solution known as LoadSpring INSIGHTS™. This groundbreaking platform...

Continue Reading